Premium Nahrungsergänzungsmittel | artgerecht

Uridine Biosynthesis – Pathway, Function & Clinical Role

Uridine biosynthesis is a key metabolic pathway through which the body produces the pyrimidine nucleoside uridine. It is essential for RNA production, cell growth, and numerous other cellular processes.

Regular tips about health Regular tips about health

Things worth knowing about "Uridine Biosynthesis"

Uridine biosynthesis is a key metabolic pathway through which the body produces the pyrimidine nucleoside uridine. It is essential for RNA production, cell growth, and numerous other cellular processes.

What Is Uridine Biosynthesis?

Uridine biosynthesis refers to the biochemical process by which the human body produces uridine – a pyrimidine nucleoside – on its own. Uridine is a fundamental building block of ribonucleic acid (RNA) and is also required for a wide range of metabolic reactions, including the synthesis of glycoproteins and glycolipids. The biosynthesis of uridine proceeds via the de novo synthesis pathway, in which simple precursor molecules are stepwise converted into uridine monophosphate (UMP).

Biological Importance

Beyond its structural role in RNA, uridine participates in the regulation of energy metabolism and neurotransmission in the nervous system. In the brain, uridine can contribute to the synthesis of phosphatidylcholine, a key component of cell membranes. Additionally, uridine is involved in the activation of sugar molecules required for building polysaccharides and glycoproteins.

Steps of the De Novo Synthesis Pathway

The de novo uridine biosynthesis pathway consists of six enzymatic steps and takes place primarily in the cytoplasm of cells:

Step 1 – Carbamoyl Phosphate Synthesis: The enzyme carbamoyl phosphate synthetase II (CPS II) catalyzes the formation of carbamoyl phosphate from glutamine, CO₂, and ATP in the cytosol.
Step 2 – Formation of Carbamoyl Aspartate: Aspartate transcarbamoylase (ATCase) transfers the carbamoyl group to aspartate, producing carbamoyl aspartate.
Step 3 – Ring Closure to Dihydroorotate: Dihydroorotase catalyzes the ring closure reaction to form dihydroorotate.
Step 4 – Oxidation to Orotate: Dihydroorotate dehydrogenase (DHODH) oxidizes dihydroorotate to orotate. This enzyme is located in the inner mitochondrial membrane and represents the only mitochondrial step in the pathway.
Step 5 – Attachment of Ribose-5-Phosphate: UMP synthase (UMPS) catalyzes two sequential reactions – orotate phosphoribosyltransferase and OMP decarboxylase – linking orotate to PRPP (phosphoribosyl pyrophosphate) and decarboxylating the product to yield uridine monophosphate (UMP).
Step 6 – Phosphorylation to UDP and UTP: UMP is further phosphorylated by kinases to UDP and then to UTP, the active nucleotide form used in RNA synthesis.

In humans, the first three steps are catalyzed by a single multifunctional enzyme known as the CAD protein (carbamoyl phosphate synthetase – aspartate transcarbamoylase – dihydroorotase).

Regulation of Uridine Biosynthesis

Uridine biosynthesis is tightly regulated to prevent overproduction of pyrimidine nucleotides:

Feedback Inhibition: UTP, as the end product, inhibits carbamoyl phosphate synthetase II (CPS II), thereby downregulating the first step of the pathway.
Activation by PRPP: Phosphoribosyl pyrophosphate (PRPP) activates CPS II and promotes synthesis when sufficient substrate is available.
Cell Growth and Proliferation: In rapidly dividing cells such as tumor cells, DHODH activity is often elevated, making this enzyme an attractive therapeutic target.

Clinical Relevance and Pharmacological Significance

Disruptions in uridine biosynthesis can lead to serious disorders. A well-known example is orotic aciduria, a rare inherited metabolic disorder caused by a defect in the UMP synthase enzyme. This prevents the further metabolism of orotate, resulting in excretion of orotic acid in the urine, megaloblastic anemia, and developmental delays.

Pharmacologically, uridine biosynthesis is highly relevant, as several drugs specifically target this pathway:

Leflunomide and Teriflunomide: These agents inhibit dihydroorotate dehydrogenase (DHODH) and are used to treat rheumatoid arthritis and multiple sclerosis, respectively. By blocking DHODH, they suppress the proliferation of activated lymphocytes.
5-Fluorouracil (5-FU): This cytostatic drug interferes with pyrimidine metabolism and is widely used in cancer therapy.
Uridine Supplementation: In patients treated with DHODH inhibitors, uridine supplementation can help mitigate side effects, as peripheral tissues can utilize uridine via the salvage pathway.

The Salvage Pathway as an Alternative

In addition to de novo synthesis, the body can also obtain uridine through the salvage pathway. In this route, preexisting pyrimidine nucleosides and nucleotides are recycled and phosphorylated to UMP. This pathway is more energy-efficient and is particularly active in tissues with limited de novo synthesis capacity, such as red blood cells and brain cells.

References

Berg JM, Tymoczko JL, Stryer L. Biochemistry. 9th edition. W. H. Freeman and Company, 2019. Chapter on nucleotide biosynthesis.
Löffler G, Petrides PE, Heinrich PC (eds.). Biochemie und Pathobiochemie. 9th edition. Springer Medizin Verlag, 2014.
Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Journal of Biological Chemistry. 1995;270(50):29682-29689. PubMed PMID: 8530355.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.